文献速递浆细胞疾病造血干细胞移植与细胞治疗

复发难治多发性骨髓瘤接受西达基奥仑赛治疗的早期治疗失败研究

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
PubMed 文献 · Am J Hematol · 2026-06-25

本研究在三个Mayo诊所中心回顾性分析接受标准治疗西达基奥仑赛的复发难治多发性骨髓瘤患者,探讨12个月内早期进展或死亡的临床因素。结果显示既往BCMA靶向治疗、髓外病变和CAR-HEMATOTOX评分≥2为独立预测因素,3个月时MRD阳性或FDG PET/CT未达完全缓解也增加早期失败风险。

要点

  • 既往BCMA靶向治疗、髓外病变和CAR-HEMATOTOX评分≥2是早期进展或死亡的独立预测因素。
  • 3个月时骨髓MRD阳性或FDG PET/CT未达完全缓解与早期治疗失败风险增高相关。
  • 西达基奥仑赛用于较早线数(1-3线)与4线及以上相比,12个月PFS无显著差异。

核心结论

  • 尽管西达基奥仑赛高效,部分复发难治多发性骨髓瘤患者仍在12个月内出现早期进展或死亡,需识别高危因素。

研究设计与样本

  • 回顾性研究,纳入三个Mayo诊所中心接受标准治疗西达基奥仑赛且随访至少12个月或12个月内进展/死亡的患者。
  • 早期治疗失败组52例,无早期治疗失败组164例。

主要发现

  • 早期治疗失败组中69%为疾病进展,31%为非复发死亡;无早期治疗失败组中13%事件为非复发死亡。
  • 既往BCMA靶向治疗、髓外病变和CAR-HEMATOTOX评分≥2是早期进展或死亡的独立预测因素。
  • 西达基奥仑赛用于1-3线 vs 4线及以上,12个月PFS分别为73% vs 77%(p=0.94)。
  • 3个月时骨髓MRD阳性(11/197例)与早期治疗失败风险增高相关(OR 5.68;p=0.012)。
  • 3个月时FDG PET/CT未达完全缓解与早期治疗失败风险增高相关(OR 11.8;p<0.0001)。

临床怎么用

  • 可依据既往BCMA靶向治疗、髓外病变、CAR-HEMATOTOX评分≥2识别早期失败高危患者。
  • 3个月时评估骨髓MRD和FDG PET/CT有助于识别早期治疗失败高风险患者。
  • 对高危患者可考虑在临床试验中探索新型治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ciltacabtagene autoleucel (cilta-cel) has demonstrated excellent efficacy and long-term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard-of-care cilta-cel across the three Mayo clinic centers. Patients with a follow-up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure (n = 52), 69% had progressive disease and 31% had a non-relapse mortality (NRM) event. In patients without early treatment failure (n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA-directed therapy, presence of extramedullary disease and a CAR-HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta-cel in earlier lines of treatment (1-3 vs. 4 or more) demonstrated comparable PFS (12-month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high-risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high-risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lim KJC, Kumar S, Parrondo R, et al. Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma. Am J Hematol. 2026. PMID: 42351384. doi:10.1002/ajh.70425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。